Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: A Bayesian network meta-analysis of randomized controlled trials

Lupus

Volumn 24, Issue 14, 2015, Pages 1520-1528

  Lee, Y H ^a   Song, G G ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

CYC; lupus nephritis; MMF; network meta analysis; Tacrolimus

Indexed keywords

CYCLOPHOSPHAMIDE; MYCOPHENOLATE MOFETIL; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ARTICLE; BAYES THEOREM; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; META ANALYSIS; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; LUPUS NEPHRITIS; PROCEDURES; TREATMENT OUTCOME;

BAYES THEOREM; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TACROLIMUS; TREATMENT OUTCOME;

EID: 84947274484     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315595131     Document Type: Article

References (36)

1. Waldman M, Appel GB,. Update on the treatment of lupus nephritis. Kidney Int 2006; 70: 1403-1412.
2. Neumann K, Wallace DJ, Azen C, et al. Lupus in the 1980s: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center. Semin Arthritis Rheum 1995; 25: 47-55.
3. Petri M,. Cyclophosphamide: New approaches for systemic lupus erythematosus. Lupus 2004; 13: 366-371.
4. Ong LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 2005; 10: 504-510.
5. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987; 40: 1256-1265.
6. Mok CC, Ying KY, Yim CW, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: A randomised controlled trial and long-term follow-up. Ann Rheum Dis 2014. Epub ahead of print 30 December. DOI: 10.1136/annrheumdis-2014-206456.
7. Feng X, Gu F, Chen W, et al. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis. Chin Med J (Engl) 2014; 127: 3718-3723.
8. Li X, Ren H, Zhang Q, et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant 2012; 27: 1467-1472.
9. Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis 2011; 57: 235-244.
10. El-Shafey EM, Abdou SH, Shareef MM,. Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients? Clin Exp Nephrol 2010; 14: 214-221.
11. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-1112.
12. Wang J, Hu W, Xie H, et al. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: Mycophenolate mofetil or intravenous cyclophosphamide. Lupus 2007; 16: 707-712.
13. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228.
14. Lee YH, Bae SC, Choi SJ, Ji JD, Song GG,. Associations between vitamin D receptor polymorphisms and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: A meta-analysis. Mol Biol Rep 2011; 38: 3643-3651.
15. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG,. PADI4 polymorphisms and rheumatoid arthritis susceptibility: A meta-analysis. Rheumatol Int 2007; 27: 827-833.
16. Catalá-López F, Tobías A, Cameron C, Moher D, Hutton B,. Network meta-analysis for comparing treatment effects of multiple interventions: An introduction. Rheumatol Int 2014; 34: 1489-1496.
17. Caldwell DM, Ades A, Higgins J,. Simultaneous comparison of multiple treatments: Combining direct and indirect evidence. BMJ 2005; 331: 897.
18. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
19. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med 2009; 151: 264-269.
20. Brown S, Hutton B, Clifford T, et al. A Microsoft-Excel-based tool for running and critically appraising network meta-analyses-an overview and application of NetMetaXL. Syst Rev 2014; 3: 110.
21. Salanti G, Ades A, Ioannidis JP,. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial. J Clin Epidemiol 2011; 64: 163-171.
22. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades A,. Evidence synthesis for decision making 4: Inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 2013; 33: 641-656.
23. Higgins J, Jackson D, Barrett J, Lu G, Ades A, White I,. Consistency and inconsistency in network meta-analysis: Concepts and models for multi-arm studies. Res Synth Methods 2012; 3: 98-110.
24. Valkenhoef G, Lu G, Brock B, Hillege H, Ades A, Welton NJ,. Automating network meta-analysis. Res Synth Methods 2012; 3: 285-299.
25. Sundel R, Solomons N, Lisk L,. Aspreva Lupus Management Study (ALMS) Group. Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: Evidence from a two-phase, prospective randomized trial. Lupus 2012; 21: 1433-1443.
26. Sinclair A, Appel G, Dooley MA, et al. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: Rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 2007; 16: 972-980.
27. Appel AS, Appel GB,. An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases. Nat Clin Pract Nephrol 2009; 5: 132-142.
28. Tang Z, Yang G, Yu C, et al. Effects of mycophenolate mofetil for patients with crescentic lupus nephritis. Nephrology 2008; 13: 702-707.
29. Lau KK, Ault BH, Jones DP, Butani L,. Induction therapy for pediatric focal proliferative lupus nephritis: Cyclophosphamide versus mycophenolate mofetil. J Pediatr Health Care 2008; 22: 282-288.
30. Wang S, Li X, Qu L, et al. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: A non-randomized prospective cohort study. Lupus 2012; 21: 1025-1035.
31. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162.
32. Chan TM, Tse KC, Tang CS, Mok MY, Li FK,. Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084.
33. Tian SY, Feldman BM, Beyene J, Brown PE, Uleryk EM, Silverman ED,. Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: A systematic review and network metaanalysis. J Rheumatology 2014; 41: 1998-2007.
34. Henderson LK, Masson P, Craig JC, et al. Induction and maintenance treatment of proliferative lupus nephritis: A meta-analysis of randomized controlled trials. Am J Kidney Dis 2013; 61: 74-87.
35. Deng J, Huo D, Wu Q, Yang Z, Liao Y,. A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis. Tohoku J Exp Med 2012; 227: 281-288.
36. Mohan S, Radhakrishnan J,. Geographical variation in the response of lupus nephritis to mycophenolate mofetil induction therapy. Clin Nephrol 2011; 75: 233-241.